Ceftaroline Fosamil 7-Position Side Chain CAS 75028-24-9 Purity: ≥99.0% (HPLC)

Short Description:

(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetic acid; Ceftaroline Fosamil 7-Position Side Chain

CAS: 75028-24-9

Purity: ≥99.0% (HPLC)

Appearance: White to Light Yellow Crystalline Powder

Intermediate of Ceftaroline Fosamil (TAK-599), a Cephalosporin derivative

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Manufacturer Supply with High Purity and Stable Quality
Chemical Name: (Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetic acid
CAS: 75028-24-9

Chemical Properties:

Chemical Name	(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetic acid
Synonyms	Ceftaroline Fosamil 7-Position Side Chain; ATDE
CAS Number	75028-24-9
CAT Number	RF-PI559
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C6H8N4O3S
Molecular Weight	216.22
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	White to Light Yellow Crystalline Powder
Purity / Analysis Method	≥99.0% (HPLC)
Moisture (K.F)	≤0.50%
Single Impurity	≤0.50%
Total Impurities	≤1.0%
Test Standard	Enterprise Standard
Usage	Intermediate of Ceftaroline Fosamil (TAK-599), a Cephalosporin derivative

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

FAQ:

Application:

(Z)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-(ethoxyimino)acetic acid (CAS: 75028-24-9) is an important intermediate for the preparation of Ceftaroline Fosamil (TAK-599). Ceftaroline fosamil is a cephalosporin with activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Ceftaroline Fosamil is a prodrug of Ceftaroline. It is being developed by Forest Laboratories, under a license from Takeda. It received approval from the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections on 29 October 2010.